Horse Racing News
Posted 3/29/14 3:48 PM by Claire Novak
Repole Stable's Micromanage seemed to have forgotten the way to the winner's circle, but he found it again March 29 in South Florida when galloping clear in the $100,000 Skip Away Stakes at Gulfstream Park.
Hey Leroy. Making his stakes debut in Saturday's Grade 3, $100,000 Appleton Stakes at Gulfstream Park.
Godolphin Racing LLC's Anjaz returned from more than a seven month layoff to capture her first stakes in the United States in Saturday's Grade 3, $150,000 Orchid Stakes at Gulfstream Park.
Winchell Thoroughbreds LLC's homebred Untapable continued to put on a show at Fair Grounds Saturday when romping home a 7 3/4-length winner of the Grade 2, $384,000 Fair Grounds Oaks.
Posted 3/29/14 2:42 PM by Myra Lewyn
Devil's Cave did all her running from the start as the 1-2 favorite in the $150,000 Rampart Stakes (gr. III) at Gulfstream Park on March 29, so stablemate Gamay Noir picked up the pieces in deep stretch to win at odds of 49-1.
Wertheimer and Frere's homebred In Tune captured her stakes debut in Saturday's Grade 2, $300,000 Gulfstream Oaks
Posted 3/29/14 12:25 PM by Jack Shinar
Godolphin Racing's African Story was guided off the inside at the head of the straight to overtake pacesetter Mukhadram en route to a comfortable victory in the $10 million Dubai World Cup Sponsored by Emirates Airline March 29 at Meydan.
Posted 3/29/14 12:23 PM by Myra Lewyn
Checked twice in the final 250 meters, Japan's star mare Gentildonna showed just what she's made of March 29 in wearing down Cirrus des Aigles and winning the $5 million Dubai Sheema Classic Presented by Longines at Meydan Racecourse.
Posted 3/29/14 11:47 AM by Frank Angst
Reddam Racing's Bond Holder, winner of the Grade 1 FrontRunner Stakes, has been scratched out of the Feb. 22 Risen Star Stakes after suffering an injury en route to Fair Grounds Race Course & Slots.
Posted 3/27/14 2:29 PM by Tom LaMarra and Esther Marr
People for the Ethical Treatment of Animals said it will "go away" if horse racing addresses its medication issues, and industry officials who have spent countless hours trying to do just that suggest progress is evident but not recognized.